TargetMol

Ilatreotide

Product Code:
 
TAR-TP2387
Product Group:
 
Peptides
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP2387-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2387-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ilatreotide is a Amadori compound of octreotide.
CAS:
119719-11-8
Molecular Weight:
1343.53
Purity:
0.98
SMILES:
CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(Cc2ccccc2)NCC2(O)OCC(O)C(OC3OC(CO)C(O)C(O)C3O)C2O)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1

References

Cuyle PJ, Engelen A, Moons V, Tollens T, Carton S. Lanreotide in the prevention and management of high-output ileostomy after colorectal cancer surgery. J Drug Assess. 2018 May 23;7(1):28-33. doi: 10.1080/21556660.2018.1467916. eCollection 2018. PubMed PMID: 29888099; PubMed Central PMCID: PMC5990955. Tena I, Gupta G, Tajahuerce M, Benavent M, Cifri?n M, Falcon A, Fonfria M, Del Olmo M, Reboll R, Conde A, Moreno F, Balaguer J, Ca?ete A, Palas? R, Bello P, Marco A, Ponce JL, Merino JF, Llombart A, Sanchez A, Pacak K. Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clin Med Insights Oncol. 2018 Apr 9;12:1179554918763367. doi: 10.1177/1179554918763367. eCollection 2018. PubMed PMID: 29720885; PubMed Central PMCID: PMC5922490. Woodmansee WW, Gordon MB, Molitch ME, Ioachimescu AG, Carver DW, Mirakhur B, Cox D, Salvatori R. Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine. 2018 May 16. doi: 10.1007/s12020-018-1615-3. [Epub ahead of print] PubMed PMID: 29767287. Pusceddu S, Vernieri C, Di Maio M, et al. Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30443-8. doi: 10.1053/j.gastro.2018.04.010. [Epub ahead of print] PubMed PMID: 29655834.